Table 3.
Spontaneous Decline of Viremia and Viral Clearance after Initiation of Potent Antiretroviral Therapy
| Subject (PID) | Spontaneous viral decay | Potent ARV Rx (down slope) | Off ARV Rx (up slope) | |||
|---|---|---|---|---|---|---|
| α/d | t 1/2(d) | δI/d | t 1/2(d) | r/d | t 2(d) | |
| 001 | 0.8 | 0.9 | 0.3 | 2.3 | 0.5 | 1.3 |
| 002 | 0.1 | 12.3 | 0.5 | 1.3 | 0.4 | 1.5 |
| 004 | 0.4 | 1.6 | 0.4 | 1.6 | – | – |
| 044 | 0.3 | 2.1 | 0.5 | 1.4 | – | – |
| 045 | 0.4 | 1.9 | 0.3 | 2.5 | – | – |
| 054 | 0.3 | 2.1 | 0.3 | 2.1 | – | – |
| 056 | 0.5 | 1.5 | 0.2 | 3.0 | – | – |
| 059 | 0.1 | 5.2 | – | – | – | – |
| Mean | 0.3 | 2.4 | 0.3 | 1.9 | 0.4 | 1.4 |
Spontaneous decay (α) was measured from the slope of observed viral decay between the peak of viremia and subsequent 10 d of follow-up. t 1/2, half life; t 2, doubling time. Phase 1 viral decay rate in the setting of potent therapy (δI) is measured from the slope of the observed viral decay between the start date of therapy and subsequent 14 d of follow-up. The rate of rise of viremia (r) after treatment interruption was measured from the slope of observed relapse of viremia between the date of therapy interruption and the next 7–14 d of follow-up. All means are geometric means.